Compare Cytokinetics Inc (CYTK) vs ProShares UltraPro QQQ ETF (TQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs ProShares UltraPro QQQ ETF — how do they compare? Cytokinetics Inc trades at $82.35 (market cap $11.12B), while ProShares UltraPro QQQ ETF trades at $73.47. The key difference: Cytokinetics Inc is trading nearer its 52-week high, ProShares UltraPro QQQ ETF nearer its low. Which is the better fit depends on your goals.
| CYTK | TQQQ | |
|---|---|---|
Market Cap | $11.12B | — |
Sector | Technology | Leveraged / Inverse |
52-Week High | $87.26 | $87.22 |
52-Week Low | $33.23 | $37.89 |
Enterprise Value | $11.59B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
TQQQ, a 3x leveraged ETF tracking the Nasdaq-100, trades at $72.64, down 5.7% in the last 24 hours amid a bearish technical signal. The fund lacks traditional financial ratios as it is not a company, and recent news highlights concerns over volatility amplification and hidden costs. Support is seen at $72, with resistance at $74.
Outlook is cautious due to leveraged structure magnifying losses in downturns; opportunities exist for tactical traders during tech rallies, but risks include daily rebalancing decay and market volatility. Long-term holders face significant drawdown risks, as seen in 2022's 81% drop versus Nasdaq's 33% decline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About ProShares UltraPro QQQ ETF
TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →
